XRT signs electron microscope deal with Gatan
02 June, 2005 by Ruth BeranUnlisted imaging company XRT, an investee of BioTech Capital (ASX:BTC), has entered a deal with Californian-based electron microscope accessory and software manufacturer Gatan to develop and distribute an x-ray microscope product for use with electron microscopes.
New members named to biotech advisory council
01 June, 2005 by Ruth BeranFour new members have been appointed to the Australian Biotechnology Advisory Council (ABAC) -- the independent board of industry experts advising the government on biotech issues.
Aust biotech posts three-year performance low: PwC
31 May, 2005 by Ruth BeranA new report on ASX-listed life sciences companies by PricewaterhouseCoopers shows that the sector has posted its worst quarterly performance in three years.
M&A's great -- but beware of the pitfalls
27 May, 2005 by Renate KrelleWith many biotechnology companies struggling to find investor support, the idea of banding together against the harsh elements -- merging or acquiring a like company -- is gaining currency. But there are many snares for the unwary, warns mergers and acquisitions specialist Nathan Drona.
Academy elects 16 new members
24 May, 2005 by Graeme O'NeillInternationally renowned molecular geneticist Dr Robin Holliday is among 16 Australian scientists elected this month to the Australian Academy of Science.
Liability clauses to be removed from CRC contract
23 May, 2005 by Ruth BeranThe federal government is to remove a controversial liability clause from Commonwealth contracts with new Cooperative Research Centres (CRCs), education minister Brendan Nelson told delegates at last week's 2005 CRC Association Conference in Melbourne.
In brief: Benitec, Probiomics, Progen, Avastra
23 May, 2005 by Renate KrelleQueensland Investment Corporation has ceased to be a substantial shareholder in Benitec (ASX:BLT), but millionaire Richard Pratt's Thorney Group has upped its holding in the company to 11.54 per cent.
What Alan Finkel did next
23 May, 2005 by Ruth BeranRuth Beran discovers how one of Australia's great bioentrepreneurs has moved from inspiring shareholders to inspiring a nation.
How to build your own Axon Instruments
23 May, 2005 by Alan FinkelAustralian Biotechnology News journalist Ruth Beran asked Axon Instruments founder Alan Finkel if he had any advice for Australian companies with an eye on the world stage. Here is his reply.
NZ budget boosts R&D
20 May, 2005 by Graeme O'NeillNew Zealand's biotechnology industry has welcomed a "solid incremental improvement" in S&T funding in this week's NZ budget.
Govt R&D investment continues to slip
20 May, 2005 by Graeme O'NeillThe Federation of Australian Scientific and Technological Societies (FASTS) has warned that Commonwealth investment in research and development will drop below 0.6 per cent of gross domestic product as a result this month's federal budget.
'Heavy-hearted' Smith steps down from Amrad
20 May, 2005 by Renate KrellePete Smith has resigned as CEO of Amrad (ASX:AML), along with chairman Bob Moses as chairman, following a board meeting yesterday.
Chief scientist quits
17 May, 2005 by Ruth BeranChief scientist, Dr Robin Batterham, has accepted a full time position with Rio Tinto and will not seek reappointment as Australia's senior science advisor for a third term.
Back into the abyss: biotech hits funding crunch
12 May, 2005 by Ruth BeranBiotech companies which have failed to raise enough capital to see them through to the next funding cycle might expire as a funding drought sets in, and blame "shocking" market conditions for forcing them to abandon or change their plans.
Industry welcomes govt's VC review commitment
11 May, 2005 by Ruth BeranThe federal government has used last night's budget to confirm its 2004 election commitment to reviewing the venture capital industry in Australia.
